labetalol has been researched along with indoramin in 16 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 10 (62.50) | 18.7374 |
| 1990's | 1 (6.25) | 18.2507 |
| 2000's | 3 (18.75) | 29.6817 |
| 2010's | 2 (12.50) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Topliss, JG; Yoshida, F | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Choi, SS; Contrera, JF; Hastings, KL; Kruhlak, NL; Sancilio, LF; Weaver, JL; Willard, JM | 1 |
| Glen, RC; Lowe, R; Mitchell, JB | 1 |
| Cantin, LD; Chen, H; Kenna, JG; Noeske, T; Stahl, S; Walker, CL; Warner, DJ | 1 |
| Rietbrock, N; Woodcock, BG | 1 |
| Littler, WA; Smith, SA | 1 |
| Dollery, CT; Warren, JB | 1 |
| Reid, JL; Rubin, PC | 1 |
| Anand, MP | 1 |
| Birkenhäger, WH; De Leeuw, PW | 1 |
| Graham, RM | 1 |
| Drayer, JI; Weber, MA | 1 |
| McAdams, RP | 1 |
| Harron, DW; Leahey, WJ; McNeill, J; Nicholls, DP; O'Connor, PC; Shanks, RG | 1 |
| Heintz, B; Kirsten, D; Kirsten, R; Nelson, K | 1 |
7 review(s) available for labetalol and indoramin
| Article | Year |
|---|---|
Antihypertensive agents--the race for third place.
Topics: Adrenergic alpha-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Calcium Channel Blockers; Captopril; Diazoxide; Felodipine; Humans; Hydralazine; Indoramin; Labetalol; Minoxidil; Nicardipine; Nifedipine; Vasodilator Agents; Verapamil | 1985 |
The usefulness of alpha-adrenoceptor blockade in the treatment of hypertension.
Topics: Adrenergic alpha-Antagonists; Antihypertensive Agents; Humans; Hypertension; Indoramin; Labetalol; Piperazines; Prazosin | 1988 |
Hypertension--drug management.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Calcium Channel Blockers; Captopril; Diazoxide; Humans; Hypertension; Indoramin; Labetalol; Minoxidil; Nifedipine; Nitroprusside; Prazosin; Sympatholytics; Vasodilator Agents; Verapamil | 1982 |
Alpha-adrenergic blockade in the treatment of essential hypertension.
Topics: Adrenergic alpha-Antagonists; Biomechanical Phenomena; Hemodynamics; Humans; Hypertension; Indoramin; Labetalol; Phenoxybenzamine; Prazosin; Receptors, Adrenergic, alpha | 1983 |
Selective alpha 1-adrenergic antagonists: therapeutically relevant antihypertensive agents.
Topics: Adrenergic alpha-Antagonists; Ethanolamines; Humans; Hypertension; Indoramin; Labetalol; Prazosin; Receptors, Adrenergic, alpha; Vascular Resistance | 1984 |
Central and peripheral blockade of the sympathetic nervous system.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Antihypertensive Agents; Blood Pressure; Clonidine; Diuretics; Drug Therapy, Combination; Guanabenz; Humans; Hypertension; Indoramin; Labetalol; Methyldopa; Prazosin; Quinazolines; Reserpine; Sympathetic Nervous System; Sympatholytics | 1984 |
Clinical pharmacokinetics of vasodilators. Part II.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Agonists; Alprostadil; Amrinone; Carbazoles; Carvedilol; Enoximone; Female; Humans; Iloprost; Imidazoles; Indoramin; Isosorbide Dinitrate; Labetalol; Milrinone; Molsidomine; Nitroglycerin; Nitroprusside; Oxyfedrine; Pentaerythritol Tetranitrate; Phosphodiesterase Inhibitors; Piperazines; Prazosin; Pregnancy; Propanolamines; Pyridones; Theophylline; Trapidil; Vasodilator Agents | 1998 |
9 other study(ies) available for labetalol and indoramin
| Article | Year |
|---|---|
QSAR model for drug human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Topics: | 2008 |
Predicting phospholipidosis using machine learning.
Topics: Animals; Artificial Intelligence; Databases, Factual; Drug Discovery; Humans; Lipidoses; Models, Biological; Phospholipids; Support Vector Machine | 2010 |
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Humans; Quantitative Structure-Activity Relationship | 2012 |
[Circadian rise of blood pressure and combined alpha-beta adrenoceptor blockade].
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Circadian Rhythm; Cold Temperature; Drug Therapy, Combination; Humans; Hypertension; Indoramin; Labetalol; Prazosin; Propranolol | 1985 |
Alpha-blockers and converting enzyme inhibitors.
Topics: Adrenergic alpha-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Captopril; Heart Failure; Humans; Hypertension; Indoramin; Kinetics; Labetalol; Prazosin | 1983 |
The effect of temperature on the alpha-adrenoceptor antagonist potency of indoramin and labetalol in the rat perfused mesenteric vascular bed.
Topics: Adrenergic alpha-Antagonists; Animals; Ethanolamines; Indoles; Indoramin; Labetalol; Male; Perfusion; Rats; Rats, Inbred Strains; Splanchnic Circulation; Temperature | 1984 |
Effect of indoramin, labetalol and alinidine on sympathetic function in normal man.
Topics: Adolescent; Adult; Blood Pressure; Clonidine; Ethanolamines; Heart Rate; Humans; Indoles; Indoramin; Labetalol; Male; Norepinephrine; Posture; Renin; Sympathetic Nervous System | 1984 |